Inovio Pharmaceuticals Inc. Stock Falls 21.9%, Underperforms Peers
Dow Jones2026/10/30 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. plummeted 21.9% to $0.60 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 2.9% to 25,437.00 and Dow Jones Industrial Average falling 1.1% to 51,770.31.
This was the stock's second consecutive day of losses.
Inovio Pharmaceuticals Inc. closed 77.9% short of its 52-week high of $2.72, which the company reached on December 17th.
The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 0.7% to $273.20, Statera Biopharma Inc. remained unchanged, and Pfizer Inc. rose 1.90% to $30.52.
Trading volume totaled 17.1 million, compared to the 50-day average of 3.7 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 30, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
